Significant Ownership of EVENTIDE ASSET MANAGEMENT, LLC
- Signature - Title
- /s/ Peter J. Luiso - Peter J. Luiso, General Counsel
- Location
- Boston, MA
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by EVENTIDE ASSET MANAGEMENT, LLC.
Follow Filing Activity
Follow EVENTIDE ASSET MANAGEMENT, LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from EVENTIDE ASSET MANAGEMENT, LLC
Significant Ownership of EVENTIDE ASSET MANAGEMENT, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| BBNX | Beta Bionics, Inc. | Common Stock, $0.0001 par value per share | 13% | $52,677,024 | +$9,643,640 | 5,945,488 | +22% | Eventide Asset Management, LLC | 31 Mar 2026 |
| OVID | Ovid Therapeutics Inc. | Common Stock, par value $0.001 per share | 7.3% | $36,787,902 | 12,773,577 | Eventide Asset Management, LLC | 31 Mar 2026 | ||
| XMTR | Xometry, Inc. | Class A Common Stock, par value $0.000001 per share | 6.7% | $78,356,159 | 3,151,897 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| Inventiva S.A. | Ordinary Shares, nominal value Euro 0.01 per share | 4.6% | 9,368,517 | -7.4% | Eventide Asset Management, LLC | 31 Dec 2025 | |||
| COLL | COLLEGIUM PHARMACEUTICAL, INC | Common Stock, par value $0.001 per share | 4.5% | $47,101,006 | -$14,946,218 | 1,424,282 | -24% | Eventide Asset Management, LLC | 31 Mar 2026 |
| MIRM | Mirum Pharmaceuticals, Inc. | Common Stock, par value $0.0001 per share | 4.1% | $165,372,042 | -$40,549,990 | 2,093,582 | -20% | Eventide Asset Management, LLC | 31 Dec 2025 |
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 3.7% | $4,544,189 | 1,234,834 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| NKTR | Nektar Therapeutics | Common Stock, $0.0001 par value | 3.6% | $4,921,000 | 6,650,000 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 3.5% | $2,353,200 | 2,220,000 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| CLDX | Celldex Therapeutics, Inc. | Common Stock, par value $0.001 | 2% | $30,459,938 | 1,356,186 | Eventide Asset Management, LLC | 30 Jun 2025 | ||
| EVH | Evolent Health, Inc. | Class A Common Stock, par value $0.01 per share | 0% | $7,109 | -$26,106,812 | 1,713 | -100% | Eventide Asset Management, LLC | 31 Dec 2025 |
| AURA | Aura Biosciences, Inc. | Common Stock, par value $0.00001 per share | 0% | $0 | -$22,524,940 | 0 | -100% | Eventide Asset Management, LLC | 31 Mar 2025 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Common Stock, $0.001 par value per share | 0% | $0 | -$6,399,327 | 0 | -100% | Eventide Asset Management, LLC | 31 Mar 2025 |
| VYNE | VYNE Therapeutics Inc. | Common Stock, par value $0.0001 | 0% | $0 | -$619,615 | 0 | -100% | Eventide Asset Management, LLC | 30 Sep 2025 |
Schedules 13D/G Reported by EVENTIDE ASSET MANAGEMENT, LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.